H-ECCO
08June2018

Serrated lesions in Inflammatory Bowel Disease

Magali Svrcek, H-ECCO Member

Magali Svrcek
Magali Svrcek
© ECCO

In addition to the “classical” pathway of colorectal carcinogenesis, involving development of cancer from an adenomatous precursor lesion, an alternative pathway, the serrated pathway, is now recognised to exist, and it is estimated that approximately 30% of colorectal cancers (CRC) arise via this alternative pathway [1]. In the last WHO classification, serrated polyps were classified as (i) hyperplastic polyps (HP), (ii) sessile serrated adenoma/polyps (SSA/P), with or without dysplasia, and (iii) traditional serrated adenomas (TSA). The possibility of a serrated pathway has also been suggested in colorectal carcinoma complicating Inflammatory Bowel Disease (IBD) [2–4]. Little is known concerning immunohistochemical and molecular features of serrated lesions in IBD: Data are limited to small series of patients or case reports and findings are controversial due to the rarity of the cases. However, the clinical, pathological and biological characteristics of serrated polyps in patients with IBD do seem to resemble those of their sporadic counterparts.

Posted in ECCO News, Committee News, H-ECCO, Volume 13, Issue 2

27April2018

Report on the 3rd H-ECCO IBD Masterclass at ECCO'18

Roger Feakins, H-ECCO Chair

Roger Feakins
Roger Feakins © ECCO

The 3rd Histopathologists of ECCO (H-ECCO) Masterclass took place in Vienna on February 15–16, 2018.

Since its formation in 2016, the Histology Working Group of ECCO (H-ECCO) has organised a successful annual educational Masterclass. The 3rd H-ECCO Masterclass at the 2018 ECCO Congress in Vienna ran on Thursday afternoon and Friday morning. It coincided with an important event: The official conversion of the H-ECCO Working Group to a full committee on the Thursday evening.  Attendance at the Masterclass was good (over 70 registrants) and the audience comprised a mixture of histopathologists and gastroenterologists from Europe and further afield.

Posted in ECCO News, ECCO'18, Congress News, H-ECCO, Volume 13, Issue 1

12December2017

The effects of drug treatment on colorectal mucosal histology

Vincenzo Villanacci, H-ECCO WG Member

Vincenzo VillanacciVincenzo Villanacci 
©  ECCO

The Inflammatory Bowel Diseases (IBD) Crohn’s Disease (CD) and Ulcerative Colitis (UC) are characterised by flares and remission, reflecting the pathological status of the inflamed intestinal tract. For decades, the treatment goal for IBD was the achievement of clinical response or remission. More recently, however, the normalisation of laboratory parameters and intestinal mucosa, termed mucosal healing (MH), has been considered a major target to prevent extra-intestinal complications and achieve sustained clinical remission. 

Posted in ECCO News, Committee News, H-ECCO, Volume 12, Issue 4